Oncolytics has an FDA date on the calendar - April 16 is the entire trade
The Opportunity
This is a dated, microcap-biotech regulatory-pathway story: Oncolytics is described as targeting an FDA meeting on 16 April 2026 to discuss how pelareorep could pursue a registration pathway in anal cancer. If the market buys the idea that the meeting tightens the registrational roadmap (sample size, analysis plan), the upside mechanism is a classic probability-weighting shift: timelines look more real, partnering/financing narratives feel less hand-wavy, and optionality expands. The call is LONG because pathway clarity - even before any approval - is one of the few catalysts that can move an early-stage biotech without new efficacy data.
The Timing
The tape is Mixed 62 with Crosswind Risk 72, so execution matters more than the thesis. Freshness is 75 and the headline is recent, but the due diligence flags automation/derivative risk, so the timing edge is about whether broader biotech communities pick up the same April 16 date and crowd it. The confirmation that would strengthen this is a primary company artefact (filing or IR) that pins the meeting and its agenda; the contradiction is any hint the meeting is routine or non-registrational.
The Evidence
The anchor in this bundle is an automated market summary describing the April 16 FDA meeting and a proposed pivotal-trial sizing concept (60-70 patients). The source is gurufocus.com . The report itself treats that automation as a quality risk, which is precisely why the opportunity exists: if the underlying meeting is real and not yet widely circulated, the market can still reprice the calendar. This is a timing signal, not a deep-validated clinical call.